Eric W. DittmannEric W.Dittmann

Lead counsel for Mitsubishi Tanabe in successfully conducting the first-ever Zoom Hatch-Waxman trial in the District of New Jersey, where all challenges to patents protecting Mitsubishi Tanabe’s blockbuster Invokana® diabetes medication were rejected.

Lead counsel for L’Oréal USA in obtaining a ruling that wiped out an infringement theory for all 130 L’Oréal USA products accused of infringement by the University of Massachusetts relating to patents covering methods of using adenosine.

Lead counsel for Mitsubishi Tanabe in an international arbitration involving the innovative drug product Gilenya®, ultimately obtaining a final award directing that $2 billion in royalties be paid to Mitsubishi Tanabe and awarding more than $22 million in fees and costs.

Co-lead counsel for Viking Therapeutics in securing a precedent-setting win and a seven-year exclusion order from the ITC against Ascletis in a first-of-its-kind, bet-the-company Section 337 ITC investigation and District Court litigation against Chinese entities. Those entities were accused of misappropriating hundreds of trade secrets and breaching a contract based on theft of proprietary information involving pharmaceutical formulations and clinical/preclinical information relating to non-alcoholic steatohepatitis treatments. This victory earned the Paul Hastings team the “Litigator of the Week” distinction by The American Lawyer’s Litigation Daily (on appeal).

Lead counsel for JSR Life Sciences in securing a complete victory dismissing all patent claims brought by competitor Cytiva BioProcess in the District of Delaware over JSR’s chromatography products. Eric and his team also prepared six IPRs challenging each of Cytiva’s asserted claims on two independent sets of prior art grounds and, after oral argument at the PTAB, obtained an outcome resulting in all but four claims being found unpatentable. On appeal, the Federal Circuit invalidated those remaining claims, providing JSR with a resounding win.

Lead counsel for bluebird bio Inc. and Third Rock Ventures in first securing summary judgment of noninfringement in a federal Delaware patent infringement action brought by San Rocco Therapeutics (SRT) stemming from a previously settled dispute relating to viral vectors used in gene therapies, including bluebird’s then-recently approved Zynteglo® and Lyfgenia® products. This followed on the heels of an early dismissal of a complex trade secrets dispute filed by SRT against bluebird bio Inc., Third Rock Ventures, 2seventy bio, and multiple individual defendants in Massachusetts federal court alleging multiple RICO violations premised on alleged trade secrets theft, mail and wire fraud, as well as alleged violations of federal and state antitrust laws.

Lead counsel for Inpria Corporation and JSR Corporation in successfully defeating a motion for a temporary restraining order and preliminary injunction brought by The Research Foundation for the State University of New York threatening Inpria’s very existence by seeking to enjoin Inpria’s use of dozens of patents and potentially precluding a planned acquisition of JSR (Inpria’s parent) in a $6.4 billion transaction by Japan Investment Corporation, a Japanese government-backed fund whose investments are overseen by the Japanese Ministry of Economy, Trade, and Industry.

Co-lead counsel for Helsinn Healthcare in prevailing in two separate trials relating to challenges to patents protecting Helsinn’s Aloxi® antiemetic drug product brought by more than 20 generics in multiple courts, the last of which ultimately settled on favorable terms, as well as in defeating two PGR petitions relating to its Aloxi® drug franchise.

Lead counsel for Boehringer Ingelheim in successfully briefing and arguing two IPR petitions resulting in the invalidation of method-of-treatment claims covering the drug product Humira®, both of which were affirmed on appeal.

Co-lead counsel in obtaining walk-aways from six separate generics for Boehringer Ingelheim in Hatch-Waxman litigation involving its blockbuster Pradaxa® stroke medication.

Counsel for AbbVie and Genentech jointly in securing the complete resolution of a Hatch-Waxman litigation protecting Venclexta®, a drug approved for various indications relating to the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia, which followed a resounding victory relating to a PGR and an IPR challenge by one of the generic challengers.

Counsel for Sunovion in obtaining a precedent-setting judgment of infringement and dismissal of all inequitable-conduct defenses in defending Sunovion’s Lunesta® franchise.

Lead counsel for Mitsubishi Tanabe in defeating challenges brought by multiple generics to Mitsubishi Tanabe’s patent covering Gilenya®, the first-ever oral multiple sclerosis treatment, which established new law relating to the obviousness-type double patenting doctrine.

Co-lead counsel for Boehringer Ingelheim in connection with BPCIA litigation relating to its biosimilar version of Humira®, which ultimately settled on favorable terms.

Lead counsel for BioMarin Pharmaceutical in appeals stemming from interference rulings relating to antisense oligonucleotides for treating Duchenne muscular dystrophy, which ultimately resulted in a favorable settlement that included a $35 million up-front payment and ongoing royalties.

Chambers USA

Chambers USA

Chambers Global

Life Sciences Patent Network (2026)

Life Sciences Patent Network (2025)

Managing IP (2025); finalist (2026)

LMG Life Sciences (2025)

LMG Life Sciences (2025)

WIPR''s USA Patents Rankings 2025

IAM’s Global Leaders list (2026)

IAM Patent 1000

Lawdragon

Benchmark Litigation

Managing IP

LMG Life Sciences

LMG Life Sciences (2023)

Law360

Law360

New York Law Journal